TORONTO, Sept. 14, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that its lead candidate, MSP-1014…

Source

Previous articlePerception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
Next articleWesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline